Bone Biologics Corp Warrants
BBLGW
2 hedge funds and large institutions have $1.48M invested in Bone Biologics Corp Warrants in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
1.13% less ownership
Funds ownership: 2.79% → 1.66% (-1.1%)
19% less capital invested
Capital invested by funds: $1.82M → $1.48M (-$340K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$58.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $1.48M | -$58.1K | -1,996 | -5% |
|
2
UBS Group
Zurich,
Switzerland
| $1.6K | – | – | – |
|
BBLGW Hedge Fund Activity: Q4 2024 in Review
2 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q4 2024, worth a combined $1.48M — down 19% from $1.82M a quarter earlier.
Fund positioning in BBLGW was balanced in Q4 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Citadel Advisors, cutting an estimated $58.1K.
- 2 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $1.48M of Bone Biologics Corp Warrants stock for Q4 2024, down 19% quarter-over-quarter.
- 0 funds opened new Bone Biologics Corp Warrants positions in Q4 2024 and 0 closed out.
- The largest Bone Biologics Corp Warrants seller in Q4 2024 was Citadel Advisors, an estimated $58.1K sold.
Based on aggregated 13F filings for Q4 2024.